We wrote about CRISPR Therapeutics (CRSP) on January 6 and said traders should "Continue to hold longs risking to $149 now. Our price targets are $200 and $230 for now." CRSP is now trading around $215 so I think another look at the stock is warranted and perhaps a change in strategy.
More from Investing
Avoid the beauty contest of price momentum that has arguably led to relatively large extremes of overvaluation today.
Many stocks with nosebleed valuations shot higher in response to Fed policy becoming more hawkish, while many quality cheaper names sold off.
The Fed backs off on claims that inflation is transitory and sets the stage for future rate hikes.